Biomed Watch
Industry analysis for policy, import-export platforms, medtech, clinical development, and global regulatory movement. This section is for market context, not medical advice.
What This Section Does
Policy & Platforms
China biomed policy, import-export infrastructure, and regional platform releases.
Global Regulation
FDA, EMA, WHO, and reputable industry sources with dates and source boundaries.
Market Signals
Clinical milestones, medical-device commercialization, financing, and cross-border implications.
Editorial Focus
- Shenzhen biomed import-export platform: what bottleneck does it remove?
- China vs global medtech signals: what changed this week
- How to read regulatory updates without turning them into medical advice
Quality Rule
FYZSXNB is traffic-first, but not volume-at-any-cost. A confirmed topic becomes a draft only after source checks, keyword review, useful structure, and a quality gate. WeChat, scoops, and community posts are leads, not copy sources.
Last section review: 2026-07-21.
FDA Foreign Drug Establishment Registration Guide
FDA foreign drug establishment registration: timing, site DUNS, U.S. agent and importers, annual renewal, SPL filing and approval boundaries.
Read moreFDA Labeler Code Checklist for Foreign Companies
FDA labeler code checklist covering DUNS, SPL submission routes, the 30-day update scope, and conditional two-year deactivation.
Read moreFXR0906 Clinical Trial China: Fosun Evidence Check
FXR0906 clinical trial China: what Fosun reported about NMPA clinical-trial approval, what remains unknown about Phase 1, and evidence boundaries.
Read moreFDA Global Generic Drug Affairs: Overseas Team Guide
What FDA Global Generic Drug Affairs does and does not do: Generic Drug Cluster, PSA pilot, and ANDA submission boundaries for overseas teams.
Read moreFDA Drug Registration and Listing: A Pre-Workshop Compliance Map for Manufacturers
FDA drug registration and listing compliance map: current SPL, EDRLS, and 510(j)(3) duties, plus the future 12-digit NDC timeline.
Read moreGDUFA III Controlled Correspondence: Scope, Submission Rules, and Eligibility Map for Generic Drug Developers
GDUFA III decision map for generic drug developers: controlled vs general correspondence, pre-ANDA meetings, post-CRL, PSG, and CPA boundaries.
Read moreCell and Gene Therapy BLA Readiness: What FDA’s OTP Town Hall Transcript Clarifies
FDA transcript-backed guide to CGT BLA filing readiness: pre-BLA meetings, CBER checklists, eCTD validation, and refuse-to-file prevention.
Read moreCasgevy for Children Aged 2 and Older: Direct Pediatric Evidence, FDA Extrapolation, and Long-Term Unknowns
Casgevy's July 1, 2026 FDA approval covers ages 2+, but direct pediatric data spans ages 5 to under 12. See what FDA extrapolated and what…
Read moreGLP-1 Generic Development Is Not One Pathway: A Product-by-Product Pre-Workshop Checklist
GLP-1 generic development is not one pathway. This pre-FDA/CRCG checklist covers reference products, Orange Book vs Purple Book, peptide routes, and devices.
Read moreModel-Integrated Evidence for Generic Drugs: What an FDA Meeting Request Must Explain
Before requesting an FDA MIE meeting, generic-drug developers must explain their model, evidence integration, and ICH M15 alignment. See the full checklist.
Read moreDigitally Derived Endpoints: A Sponsor Readiness Checklist Before FDA’s August 2026 Workshop
Sponsor readiness checklist for FDA's August 2026 digitally derived endpoints workshop. Covers estimands, validation, data standards, and sensitivity analysis.
Read moreFDA 2026 CGT CMC Guidance: What Is Flexible and Required
A practical guide to FDA's May 2026 CGT CMC flexibilities, PPQ, specifications, stability, platform knowledge and what BLAs still must show.
Read more